Department of Medicine
Faculty Profiles by Division

Division of Infectious Diseases

Faculty Profiles

[Return To Index page]
photo Bernard JC Macatangay, MD

Assistant Director, University of Pittsburgh Immunology Specialty Lab (ACTG)


Phone: 412-383-1272

Office: S827 Scaife Hall
3550 Terrace St
Pittsburgh, PA 15261
Phone: 412-383-1272
Fax: 412-648-8457
Administrative Assistant:
Gabriella Merritt
Address: 817 Scaife Hall
3550 Terrace Street
Pittsburgh, PA 15261
Phone: 412-383-9062
Fax: 412-648-8521
Administrative Assistant:
Patricia Paulson
Address: Keystone Bldg., 5th Fl
3520 Fifth Avenue
Pittsburgh, PA 15213
Phone: 412-383-1675
Fax: 412-383-2900
Education and Training
B.S., Biology, University of the Philippines, 1996
Doctor of Medicine, University of the Philippines, College of Medicine, 2001
Internal Medicine, Roger Williams Medical Center Boston University Program, 2006
General Infectious Diseases, University of Pittsburgh, 2008
HIV/AIDS, University of Pittsburgh, 2010
Research Interest
lmmunoregulatory mechanisms can influence many aspects of the body's immune responses to different antigens, and can control inflammatory responses, thereby preventing pathology caused by persistent immune activation and inflammation. The Macatangay laboratory focuses on various immunoregulatory pathways in different inflammatory states, especially in HIV infection. Specifically, the lab aims to define the role of different immunoregulatory mechanisms in: the inflammatory state associated with chronic HIV infection; HIV persistence; and various HIV immunotherapeutic strategies, such as in therapeutic vaccination. By using specimens obtained from the various studies at the Pittsburgh Treatment and Evaluation Unit (PTEU), the AIDS Clinical Trials Group (ACTG), and the Multicenter AIDS Cohort Study (MACS), the lab assesses the immunophenotype and frequencies of regulatory immune cell subsets. It also analyzes specific suppressive function and components of regulatory pathways to further understand the influence of specific immunoregulatory mechanisms in HIV pathogenesis and persistence. In doing so, Dr. Macatangay aims to improve existing or develop new immunotherapeutic strategies for the control of chronic HIV-associated inflammation and/or for the functional cure of HIV.
Clinical Interest
Dr. Macatangay is an HIV care provider at the Pittsburgh AIDS Center for Treatment (PACT Clinic). He also rounds on the General Infectious Diseases Consult Service at UPMC Presbyterian-Montefiore. Apart from HIV and general infectious diseases, he is interested in parasitic diseases, specifically helminthic infections.
Educational Interest
Dr. Macatangay mentors medical students, Internal Medicine residents, and Infectious Diseases Fellows in HIV immunology and parasitology research. He gives lectures on HIV Immunology, HIV Microbiology, Sexually Transmitted Infections, and Helminthic infections to first year medical students, and is a problem-based learning facilitator for Medical Microbiology. He coordinates the Tropical Medicine and Parasitology course for the Internal Medicine Global Health Track residents at UPMC Presbyterian, and provides the Helminthic Infections and HIV Immunology lectures to ID Fellows. He also lectures on the Diagnosis, Treatment, and Prevention of Helminthic Infections to MPH students at the Graduate School of Public Health.
For my complete bibliography, Click Here.
Selected Publications:
Macatangay BJ, Riddler S, Wheeler N, Spindler J, Lawani M, Hong F, Buffo M, Whiteside T, Kearney M, Mellors JW, Rinaldo C. Therapeutic vaccination with dendritic cells loaded with autologous HIV-1-infected apoptotic cells. J Inf Dis. 2016; 213(9): 1400-9.
He T, Brocca-Cofano E, Gillespie D, Xu C, Stock J, Ma D, Policicchio B, Raehtz K, Rinaldo C, Apetrei C, Jackson E, Macatangay BJ, Pandrea I. Critical role of the adenosine pathway in controlling SIV-related immune activation and inflammation in gut mucosal tissues. J Virol. 2015; 89(18): 9616-30.
Macatangay, BJC, Szajnik, ME, Whiteside, TL, Riddler, SA, Rinaldo, CR. Regulatory T cell suppression of Gag-specific CD8+ T cell polyfunctional response after therapeutic vaccination of HIV-1-infected patients on ART. PLoS One. 2010; 5(3): e9852.
Schuler, PJ, Macatangay, BJ, Saze, Z, Jackson, EK, Riddler, SA, Buchanan, WG, Hilldorfer, BB, Mellors, JW, Whiteside, TL, Rinaldo, CR. CD4+CD73+ T cells are associated with lower T-cell activation and C reactive protein levels and are depleted in HIv-1 infection regardless of viral suppression. AIDS. 2013; 27(10): 1545-1555.
Tenorio, AR, Chan, ES, Bosh, RJ, Macatangay, BJ, Read, SW, Yesmin, S, Taiwo, B, Margolis, DM, Jacobson, JM, Landay, AL, Wilson, CC. Rifaximin has a marginal impact on microbial translocation, T-cell activation, and inflammation in HIV-positive immune non-responders to antiretroviral therapy – ACTG A5286. Journal of Infectious Diseases. 2015; 211(5): 780-90.
Wada, NI, Bream, JH, Martinez-Maza, O, Macatangay, B, Galvin, SR, Margolick, JB, Jacobson, LP. Inflammatory biomarkers and mortality risk among HIV-suppressed men: A multisite prospective cohort study. Clinical Infectious Diseases. 2016; epub ahead of print.
Sponsored Research/Activities
Title: Dipyridamole as a Modulator of HIV-1 Inflammation by Adenosine Regulation
Role: Co-Principal Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI1110410
Start Year: 2014
End Year: 2018
Title: Combined Immunologic Approaches to Cure HIV-1 (Virology Core)
Role: Co-Investigator
Funding Agency: Beth Israel Deaconess
Grant Number: UM1 AI126603
Start Year: 2016
End Year: 2017
Title: University of Pittsburgh Multicenter AIDS Cohort Study (MACS)
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: U01 AI035041
Start Year: 2014
End Year: 2019
Title: Longitudinal Evaluation of HIV-Associated Lung Disease Phenotypes
Role: Co-Investigator
Funding Agency: National Heart, Lung, & Blood Institute
Grant Number: R01 HL125049
Start Year: 2014
End Year: 2018
Title: A Phase 1b, Randomized, Blinded, Placebo-Controlled Dose Escalation Study of the Safety and Biological Activity of GS-9620 in HIV-1 Infected, Virologically Suppressed Adults
Role: Co-Investigator
Funding Agency: Gilead Sciences, Inc
Grant Number: DRUG
Start Year: 2014
End Year: 2018
Title: Aids Clinical Trial Group: Core Funding
Role: Co-Investigator
Funding Agency: Brigham and Women's Hospital, Inc.
Grant Number: UM1 AI068636
Start Year: 2014
End Year: 2017
Title: Pittsburgh ACTG Immunology Specialty Laboratory
Role: Co-Investigator
Funding Agency: Brigham and Women's Hospital, Inc./National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI106701
Start Year: 2014
End Year: 2016
Title: Pitt-Ohio State - Georgetown Clinical Trials Unit
Role: Co-Investigator
Funding Agency: National Institute of Allergy & Infectious Diseases
Grant Number: UM1 AI069494
Start Year: 2013
End Year: 2020
Notable Achievements
Editorial Advisory Board member, Open Forum Infectious Diseases
Ad Hoc Review Panel Member, ZDE1 CF (10), RFA DE15-003 “Approaches to Eliminate HIV and Opportunistic Pathogens from Oral Reservoirs (R01)
Excellence in Education Award (Basic Sciences, Small Group Facilitator), University of Pittsburgh School of Medicine